CM Management’s Compass Therapeutics CMPX Stock Holding History

CM Management’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$780K	Buy	750,000 +200,000	+36%	+$412K	0.52%	56
2026 Q2	$1.2M	Buy	+550,000	New	+$1.62M	0.77%	52
2026 Q1	–	Sell	-100,000	Closed	-$537K	–	73
2025 Q4	$537K	Sell	100,000 -50,000	-33%	-$231K	0.45%	52
2025 Q3	$525K	Buy	+150,000	New	+$474K	0.44%	57
2025 Q1	–	Sell	-310,000	Closed	-$450K	–	55
2024 Q4	$450K	Hold	310,000	–	–	0.4%	51
2024 Q3	$570K	Hold	310,000	–	–	0.46%	54
2024 Q2	$310K	Hold	310,000	–	–	0.28%	59
2024 Q1	$614K	Buy	310,000 +185,000	+148%	+$320K	0.52%	53
2023 Q4	$195K	Buy	+125,000	New	+$216K	0.16%	70
2022 Q3	–	Sell	-30,000	Closed	-$80K	–	73
2022 Q2	$80K	Sell	30,000 -270,000	-90%	-$586K	0.09%	69
2022 Q1	$411K	Buy	+300,000	New	+$620K	0.35%	67

Other funds holding CMPX

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

CM Management's CMPX Position: Q3 2026 in Review

CM Management increased its Compass Therapeutics (CMPX) stake by 36% in Q3 2026, buying an estimated $412K and bringing the position to 750,000 shares worth $780K. The position accounts for 0.52% of the portfolio, ranked #56.

CM Management first reported a position in CMPX in Q1 2022 and has held it in 11 quarters since. The position peaked at $1.2M in Q2 2026. 84 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

CM Management held 750,000 shares of Compass Therapeutics worth $780K as of Q3 2026.
CM Management bought 200,000 Compass Therapeutics shares in Q3 2026, an estimated $412K.
Compass Therapeutics made up 0.52% of CM Management's portfolio in Q3 2026, its #56 holding.
CM Management first reported a position in Compass Therapeutics in Q1 2022 and has held it in 11 quarters since.
CM Management's Compass Therapeutics position peaked at $1.2M in Q2 2026.
84 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on CM Management's 13F filing for Q3 2026, filed 12 Nov 2026.